BERGEN,
Norway, Aug. 22, 2023 /PRNewswire/ -- BerGenBio
ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company
developing novel, selective AXL kinase inhibitors for severe unmet
medical needs, announced today that additional clinical data
of bemcentinib in combination with chemotherapy and with
immunotherapy in Non-Small Cell Lung Cancer (NSCLC) have been
recently published and accepted for presentation at two upcoming
international oncology
conferences:
- Comprehensive results from the investigator led trial
of bemcentininb + docetaxel in previously treated NSCLC
patients (Study BGBIL005) were published in the August 2023 issue of Lung Cancer. "Phase 1
trial of bemcentinib (BGB324), a first-in-class, selective AXL
inhibitor, with docetaxel in patients with previously treated
advanced non-small cell lung cancer." Lung Cancer 182 (2023) The
trial was led by David Gerber, MD.,
Professor at the UT Southwestern Harold C. Simmons Comprehensive
Cancer Center.
- The abstract "Bemcentinib + Pembrolizumab show promising
efficacy in metastatic NSCLC harbouring mutations associated with
poor prognosis: Exploratory sub-analysis from the BGBC008 trial
(NCT03184571)" has been accepted for
poster presentation at the SITC 38th Annual Meeting,
to be held November 3-5,
2023, in San Diego,
CA (Abstract #598).
- The abstract "Final top-line results of the BGBC008 phase 2,
multicenter study of bemcentinib and pembrolizumab (bem+pembro) in
2nd line (2L) advanced non-squamous (NS) non-small cell lung cancer
(NSCLC) (NCT03184571)" has been accepted for poster presentation at
the ESMO Congress 2023, to be held October 20-24, 2023, in Madrid, Spain (Abstract #5343)
"The accumulating evidence supporting the potential role of
bemcentinib in NSCLC aligns with our strategic focus on this
disease where a large portion of patients still have very poor
clinical outcome from existing therapies" said Martin Olin, Chief Executive Officer of
BerGenBio. "The publication of data in a prestigious peer reviewed
publication and at ESMO and SITC provides us with the opportunity
to share our data with a broad audience of oncologists and key
opinion leaders in the field of NSCLC and the pharmaceutical
industry."
Contacts
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio
ASA
rune.skeie@bergenbio.com
Media Relations
Jan Lilleby
jl@lillebyfrisch.no
+47 90 55 16 98
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused
on developing transformative drugs targeting AXL as a potential
cornerstone of therapy for aggressive diseases, including cancer
and severe respiratory infections. The Company is focused on its
proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11
mutated NSCLC and severe respiratory infections.
BerGenBio is based in Bergen,
Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo
Stock Exchange (ticker: BGBIO). For more information,
visit www.bergenbio.com
This information is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 of the Norwegian
Securities Trading Act.
View original
content:https://www.prnewswire.com/news-releases/bergenbio-announces-clinical-data-presentations-highlighting-the-activity-of-its-selective-axl-inhibitor-bemcentinib-in-non-small-cell-lung-cancer-301906544.html
SOURCE BerGenBio ASA